| Metric | Q2 FY27 | Q1 FY27 | Q2 FY26 |
|---|---|---|---|
| Revenue from operations | 746.5 | 570.1 | 411.6 |
| Other income | 8.7 | 5.2 | 4.6 |
| Total income | 755.2 | 575.3 | 416.2 |
| Profit before exceptional items & tax | 116.5 | 74.5 | 19.9 |
| Exceptional items | 0.0 | 0.0 | 25.8 |
| Profit before tax | 116.5 | 74.5 | 45.7 |
| Net profit | 88.9 | 56.4 | 40.9 |
| Operating margin | 15.4% | 12.9% | 11.0% |
A dash means the filing did not report that period; n/m means not meaningful (margin on near-zero revenue). Growth is not shown when either period was a loss. Operating profit excludes other income.
| Net profit, year on year | +117.40% |
|---|---|
| Net profit, quarter on quarter | +57.60% |
| Revenue, year on year | +81.40% |
| Operating profit, year on year | +604.60% |
| Operating profit, quarter on quarter | +55.60% |
NSE results filing, NSE: MOREPENLAB. Figures extracted from the filing.
Morepen Laboratories Ltd: key numbers
- Share price
- ₹125.58
- Market cap
- ₹6,881 Cr
- Revenue (annual)
- ₹1,806 Cr
- Net profit (annual)
- ₹94.88 Cr
- P/E (TTM)
- 36.5×Sector 46.5×
- Promoter holding
- 35.65%+0.00% QoQ
- FII holding
- 3.43%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Morepen Laboratories Ltd
All →Morepen Laboratories Management Change
Morepen Laboratories announced promotions effective 27 October 2026 for two senior management personnel. Charanjeet Chitakara moves to Assistant Vice President (Quality Control) and Vivan Prashar to Vice President (Projects & Engineering).
Morepen Laboratories Other Announcement
Morepen filed its Q2FY27 Monitoring Agency Report confirming Nil deviation in QIP proceeds utilization. The company spent ₹1.12 crore on modernization and expansion during the quarter.
Morepen Laboratories Investor Presentation: Key Takeaways
Q2 FY27 revenue Rs755 Cr (+81%), PAT Rs89 Cr (+117%), EBITDA margin 17.45% (+897bps). H1 revenue Rs1,330 Cr (+57%). CDMO scale-up drives mix.
Morepen Laboratories Results Update
Morepen hit record Q2 FY27 revenue up 81% and EBITDA up 273%, driven by CDMO scale-up. H1 EBITDA reached ₹220 Cr; API+CDMO capacity now 614 KL.
- API + CDMO manufacturing capacity
- 614 KL
Morepen Laboratories Board Meeting Date
Morepen Laboratories Limited announced a board meeting scheduled for October 27, 2026. The meeting will consider and approve the financial results for the quarter ended September 30, 2026.
Morepen Laboratories Legal & Regulatory
The High Court of Himachal Pradesh quashed a GST show cause notice against Morepen Laboratories, resolving a demand of ₹117.94 Crore in the company's favour.
- Value
- ₹117.9 Cr